Reporting CR for Multiple Myeloma  
Pre-TED (F2400) and Plasma Cell Disorders (F2016, F2116) Manuals

Complete remission determination for multiple myeloma recipients has been an area of confusion. The CIBMTR would like to offer clarification regarding the requirements for reporting CR. Complete remission criteria require that all of the following be met:
- Negative immunofixation on serum and urine samples
- Disappearance of any soft tissue plasmacytomas
- < 5% plasma cells in the bone marrow

For recipients with light chain only myeloma, all of the following criteria must be met:
- Normal serum free light chain ratio
- Negative immunofixation on urine samples
- Disappearance of any soft tissue plasmacytomas
- < 5% plasma cells in the bone marrow

For recipients with non-secretory myeloma, all of the following criteria must be met:
- Disappearance of all soft tissue plasmacytomas
- < 5% plasma cells in the bone marrow

Reporting a complete remission requires two consecutive assessments by the same method, made at any time before the institution of any new therapy. The method of the two consecutive assessments may be any of the biochemical tests (urine/serum testing) listed in the disease status criteria available in the manual. Though it is preferable the biochemical confirmatory testing include both the urine & serum, this disease status does not require two consecutive assessments by each method. As an example:

A recipient with IgG kappa myeloma receives therapy and has assessments performed on April 1, which appear to show resolution of disease. These include negative serum and urine immunofixations, a bone survey and PET/CT without evidence of active disease, and a negative bone marrow with 2% plasma cells. On May 1, the recipient has another negative serum immunofixation prior to proceeding with transplant on May 12. This recipient would be in complete remission at transplant, as they meet all specified CR criteria and have two consecutive negative serum immunofixation studies; additional imaging and bone marrow studies are not required.

The multiple myeloma response criteria used for CIBMTR data reporting has been adapted from the International Myeloma Working Group (IMWG). Please review the CIBMTR manual section and the source below for full multiple myeloma disease status and response criteria.

Source:

Sincerely,
CIBMTR Data Operations